Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02

AUTHORS

T. R. Jeffry Evans, Emma Dean, L. Rhoda Molife, Juanita Lopez, Malcolm Ranson, Fatima El-Khouly, Ishtiaq Zubairi, Claudio Savulsky, Larisa Reyderman, Yan Jia, Lorna Sweeting, Alastair Greystoke, Jorge Barriuso, Rebecca Kristeleit

ABSTRACT

BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5 mg/m2, with dose escalation in a 3 + 3 design. The dose-expansion phase evaluated eribulin-LF in select tumour types. PRIMARY OBJECTIVES: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF. RESULTS: Totally, 58 patients were enroled (median age = 62 years). The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses. CONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed. More... »

PAGES

379-386

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x

DOI

http://dx.doi.org/10.1038/s41416-019-0377-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111642723

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30679780


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Glasgow", 
          "id": "https://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Beatson West of Scotland Cancer Centre, Glasgow, UK", 
            "University of Glasgow, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evans", 
        "givenName": "T. R. Jeffry", 
        "id": "sg:person.013162613642.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013162613642.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "The Christie NHS Foundation Trust, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dean", 
        "givenName": "Emma", 
        "id": "sg:person.01041560063.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041560063.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molife", 
        "givenName": "L. Rhoda", 
        "id": "sg:person.01176172571.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176172571.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lopez", 
        "givenName": "Juanita", 
        "id": "sg:person.014561733511.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014561733511.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "The Christie NHS Foundation Trust, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranson", 
        "givenName": "Malcolm", 
        "id": "sg:person.01124372241.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "UCL Cancer Institute, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "El-Khouly", 
        "givenName": "Fatima", 
        "id": "sg:person.01274610707.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274610707.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beatson West of Scotland Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.422301.6", 
          "name": [
            "Beatson West of Scotland Cancer Centre, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zubairi", 
        "givenName": "Ishtiaq", 
        "id": "sg:person.07545311260.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07545311260.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eisai (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.428696.7", 
          "name": [
            "Eisai Ltd., Hatfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Savulsky", 
        "givenName": "Claudio", 
        "id": "sg:person.011515070473.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011515070473.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eisai (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Eisai Inc., Woodcliff Lake, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reyderman", 
        "givenName": "Larisa", 
        "id": "sg:person.0627241052.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627241052.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eisai (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418767.b", 
          "name": [
            "Eisai Inc., Woodcliff Lake, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jia", 
        "givenName": "Yan", 
        "id": "sg:person.07520112340.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07520112340.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beatson West of Scotland Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.422301.6", 
          "name": [
            "Beatson West of Scotland Cancer Centre, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sweeting", 
        "givenName": "Lorna", 
        "id": "sg:person.0752677326.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752677326.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Newcastle University", 
          "id": "https://www.grid.ac/institutes/grid.1006.7", 
          "name": [
            "Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greystoke", 
        "givenName": "Alastair", 
        "id": "sg:person.0773547677.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773547677.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "The Christie NHS Foundation Trust, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barriuso", 
        "givenName": "Jorge", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "UCL Cancer Institute, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kristeleit", 
        "givenName": "Rebecca", 
        "id": "sg:person.01140351721.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140351721.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.4137/bcbcr.s29421", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000921905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-014-3144-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002219105", 
          "https://doi.org/10.1007/s10549-014-3144-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-014-3144-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002219105", 
          "https://doi.org/10.1007/s10549-014-3144-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12012-007-0014-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004235755", 
          "https://doi.org/10.1007/s12012-007-0014-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.52.4892", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006959677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2013.01.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007082291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jchromb.2008.09.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011041981"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01283-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014338125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-3252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015500441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-016-0418-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020367645", 
          "https://doi.org/10.1007/s10637-016-0418-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-016-0418-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020367645", 
          "https://doi.org/10.1007/s10637-016-0418-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024546443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60070-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025413289"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2868-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028528026", 
          "https://doi.org/10.1007/s00280-015-2868-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-08-0095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029470846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1958", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035719328", 
          "https://doi.org/10.1038/nrc1958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1958", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035719328", 
          "https://doi.org/10.1038/nrc1958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bcp.2010.04.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042899186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-04-0345", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043330423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2878-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043428451", 
          "https://doi.org/10.1007/s00280-015-2878-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2878-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043428451", 
          "https://doi.org/10.1007/s00280-015-2878-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fphar.2015.00286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043813505"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi901810u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055210409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi901810u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055210409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079256316", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082752385", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.70.8297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084253732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/pharmaceutics9020012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084436901"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02", 
    "datePublishedReg": "2019-02-01", 
    "description": "BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours.\nMETHODS: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5\u2009mg/m2, with dose escalation in a 3\u2009+\u20093 design. The dose-expansion phase evaluated eribulin-LF in select tumour types.\nPRIMARY OBJECTIVES: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF.\nRESULTS: Totally, 58 patients were enroled (median age\u2009=\u200962 years). The MTD was 1.4\u2009mg/m2 (Schedule 1) or 1.5\u2009mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30\u2009h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses.\nCONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41416-019-0377-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "120"
      }
    ], 
    "name": "Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours", 
    "pagination": "379-386", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "65fd9077ede18e0759c6b4aec765d190c6b68d83c488b2c1eb7755da21557f23"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30679780"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-019-0377-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111642723"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-019-0377-x", 
      "https://app.dimensions.ai/details/publication/pub.1111642723"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000338_0000000338/records_47967_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/s41416-019-0377-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-019-0377-x'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      21 PREDICATES      53 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-019-0377-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N95f959a7d99a4cc2a0c1e092022c4729
4 schema:citation sg:pub.10.1007/s00280-015-2868-7
5 sg:pub.10.1007/s00280-015-2878-5
6 sg:pub.10.1007/s10549-014-3144-y
7 sg:pub.10.1007/s10637-016-0418-8
8 sg:pub.10.1007/s12012-007-0014-4
9 sg:pub.10.1038/nrc1958
10 https://app.dimensions.ai/details/publication/pub.1079256316
11 https://app.dimensions.ai/details/publication/pub.1082752385
12 https://doi.org/10.1016/j.bcp.2010.04.020
13 https://doi.org/10.1016/j.ejca.2008.10.026
14 https://doi.org/10.1016/j.ijpharm.2013.01.010
15 https://doi.org/10.1016/j.jchromb.2008.09.013
16 https://doi.org/10.1016/s0140-6736(11)60070-6
17 https://doi.org/10.1016/s0140-6736(15)01283-0
18 https://doi.org/10.1021/bi901810u
19 https://doi.org/10.1158/1078-0432.ccr-09-0360
20 https://doi.org/10.1158/1078-0432.ccr-14-3252
21 https://doi.org/10.1158/1535-7163.mct-04-0345
22 https://doi.org/10.1158/1535-7163.mct-08-0095
23 https://doi.org/10.1200/jco.2013.52.4892
24 https://doi.org/10.1200/jco.2016.70.8297
25 https://doi.org/10.3389/fphar.2015.00286
26 https://doi.org/10.3390/pharmaceutics9020012
27 https://doi.org/10.4137/bcbcr.s29421
28 schema:datePublished 2019-02
29 schema:datePublishedReg 2019-02-01
30 schema:description BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5 mg/m2, with dose escalation in a 3 + 3 design. The dose-expansion phase evaluated eribulin-LF in select tumour types. PRIMARY OBJECTIVES: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF. RESULTS: Totally, 58 patients were enroled (median age = 62 years). The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses. CONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf N55b19bc42c8e4367b06eae03fcf6b7f5
35 Nbf9d06f6b9d242049859407efc6ee46e
36 sg:journal.1017082
37 schema:name Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
38 schema:pagination 379-386
39 schema:productId N028c369e899f405e854e23ca2f871f0d
40 N4a4b92c25e51434aaf1df1a08193be40
41 N6f9b43adecc94820b6dd0781eca28f27
42 N8a83f37e77424b82a308201cff9729c8
43 Nb164f5c9f132469b824a9d6c866b0b96
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111642723
45 https://doi.org/10.1038/s41416-019-0377-x
46 schema:sdDatePublished 2019-04-11T09:10
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N5250a5ce6bcf4a39955df3dd5b5068a8
49 schema:url https://www.nature.com/articles/s41416-019-0377-x
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N028c369e899f405e854e23ca2f871f0d schema:name readcube_id
54 schema:value 65fd9077ede18e0759c6b4aec765d190c6b68d83c488b2c1eb7755da21557f23
55 rdf:type schema:PropertyValue
56 N03706cea3cc942eaadd6a15161adaff9 rdf:first sg:person.01140351721.10
57 rdf:rest rdf:nil
58 N214eed15b3fe4bd392f20e9cd205c0dc schema:affiliation https://www.grid.ac/institutes/grid.412917.8
59 schema:familyName Barriuso
60 schema:givenName Jorge
61 rdf:type schema:Person
62 N2c4664c560f34b63ab5de4ee91fce647 rdf:first sg:person.0773547677.71
63 rdf:rest N602f419045124756af911784759b5457
64 N304bd250b772478998a21fdbc6bc5cef rdf:first sg:person.01041560063.08
65 rdf:rest N330380e891a74825968fe5ce74c37c85
66 N316b23b2374e437a9a5f2c23622e1335 rdf:first sg:person.011515070473.83
67 rdf:rest Nd9269294e8b34b9ea5f450e44e59bf51
68 N330380e891a74825968fe5ce74c37c85 rdf:first sg:person.01176172571.54
69 rdf:rest N5727667eeeec4bca9d2fe24a9fe92b2b
70 N4a4b92c25e51434aaf1df1a08193be40 schema:name dimensions_id
71 schema:value pub.1111642723
72 rdf:type schema:PropertyValue
73 N5250a5ce6bcf4a39955df3dd5b5068a8 schema:name Springer Nature - SN SciGraph project
74 rdf:type schema:Organization
75 N55b19bc42c8e4367b06eae03fcf6b7f5 schema:volumeNumber 120
76 rdf:type schema:PublicationVolume
77 N5727667eeeec4bca9d2fe24a9fe92b2b rdf:first sg:person.014561733511.48
78 rdf:rest Ne8ea694de8004662992aa6c0e2734d29
79 N5c2d51ff095b4065aefdefc63ccf6daf rdf:first sg:person.0752677326.57
80 rdf:rest N2c4664c560f34b63ab5de4ee91fce647
81 N602f419045124756af911784759b5457 rdf:first N214eed15b3fe4bd392f20e9cd205c0dc
82 rdf:rest N03706cea3cc942eaadd6a15161adaff9
83 N6f9b43adecc94820b6dd0781eca28f27 schema:name pubmed_id
84 schema:value 30679780
85 rdf:type schema:PropertyValue
86 N7779a7081c714561bbbc49badca86635 rdf:first sg:person.01274610707.71
87 rdf:rest Ncab1c27c353744c8ba44e069be905ecf
88 N8a83f37e77424b82a308201cff9729c8 schema:name nlm_unique_id
89 schema:value 0370635
90 rdf:type schema:PropertyValue
91 N95f959a7d99a4cc2a0c1e092022c4729 rdf:first sg:person.013162613642.37
92 rdf:rest N304bd250b772478998a21fdbc6bc5cef
93 Nb164f5c9f132469b824a9d6c866b0b96 schema:name doi
94 schema:value 10.1038/s41416-019-0377-x
95 rdf:type schema:PropertyValue
96 Nbefa06f0045043cc9c32afdffa61e1cf rdf:first sg:person.07520112340.26
97 rdf:rest N5c2d51ff095b4065aefdefc63ccf6daf
98 Nbf9d06f6b9d242049859407efc6ee46e schema:issueNumber 4
99 rdf:type schema:PublicationIssue
100 Ncab1c27c353744c8ba44e069be905ecf rdf:first sg:person.07545311260.46
101 rdf:rest N316b23b2374e437a9a5f2c23622e1335
102 Nd9269294e8b34b9ea5f450e44e59bf51 rdf:first sg:person.0627241052.36
103 rdf:rest Nbefa06f0045043cc9c32afdffa61e1cf
104 Ne8ea694de8004662992aa6c0e2734d29 rdf:first sg:person.01124372241.32
105 rdf:rest N7779a7081c714561bbbc49badca86635
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
110 schema:name Clinical Sciences
111 rdf:type schema:DefinedTerm
112 sg:journal.1017082 schema:issn 0007-0920
113 1532-1827
114 schema:name British Journal of Cancer
115 rdf:type schema:Periodical
116 sg:person.01041560063.08 schema:affiliation https://www.grid.ac/institutes/grid.412917.8
117 schema:familyName Dean
118 schema:givenName Emma
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041560063.08
120 rdf:type schema:Person
121 sg:person.01124372241.32 schema:affiliation https://www.grid.ac/institutes/grid.412917.8
122 schema:familyName Ranson
123 schema:givenName Malcolm
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32
125 rdf:type schema:Person
126 sg:person.01140351721.10 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
127 schema:familyName Kristeleit
128 schema:givenName Rebecca
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140351721.10
130 rdf:type schema:Person
131 sg:person.011515070473.83 schema:affiliation https://www.grid.ac/institutes/grid.428696.7
132 schema:familyName Savulsky
133 schema:givenName Claudio
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011515070473.83
135 rdf:type schema:Person
136 sg:person.01176172571.54 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
137 schema:familyName Molife
138 schema:givenName L. Rhoda
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176172571.54
140 rdf:type schema:Person
141 sg:person.01274610707.71 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
142 schema:familyName El-Khouly
143 schema:givenName Fatima
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274610707.71
145 rdf:type schema:Person
146 sg:person.013162613642.37 schema:affiliation https://www.grid.ac/institutes/grid.8756.c
147 schema:familyName Evans
148 schema:givenName T. R. Jeffry
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013162613642.37
150 rdf:type schema:Person
151 sg:person.014561733511.48 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
152 schema:familyName Lopez
153 schema:givenName Juanita
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014561733511.48
155 rdf:type schema:Person
156 sg:person.0627241052.36 schema:affiliation https://www.grid.ac/institutes/grid.418767.b
157 schema:familyName Reyderman
158 schema:givenName Larisa
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627241052.36
160 rdf:type schema:Person
161 sg:person.07520112340.26 schema:affiliation https://www.grid.ac/institutes/grid.418767.b
162 schema:familyName Jia
163 schema:givenName Yan
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07520112340.26
165 rdf:type schema:Person
166 sg:person.0752677326.57 schema:affiliation https://www.grid.ac/institutes/grid.422301.6
167 schema:familyName Sweeting
168 schema:givenName Lorna
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752677326.57
170 rdf:type schema:Person
171 sg:person.07545311260.46 schema:affiliation https://www.grid.ac/institutes/grid.422301.6
172 schema:familyName Zubairi
173 schema:givenName Ishtiaq
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07545311260.46
175 rdf:type schema:Person
176 sg:person.0773547677.71 schema:affiliation https://www.grid.ac/institutes/grid.1006.7
177 schema:familyName Greystoke
178 schema:givenName Alastair
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773547677.71
180 rdf:type schema:Person
181 sg:pub.10.1007/s00280-015-2868-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028528026
182 https://doi.org/10.1007/s00280-015-2868-7
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/s00280-015-2878-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043428451
185 https://doi.org/10.1007/s00280-015-2878-5
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s10549-014-3144-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1002219105
188 https://doi.org/10.1007/s10549-014-3144-y
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s10637-016-0418-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020367645
191 https://doi.org/10.1007/s10637-016-0418-8
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s12012-007-0014-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004235755
194 https://doi.org/10.1007/s12012-007-0014-4
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/nrc1958 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035719328
197 https://doi.org/10.1038/nrc1958
198 rdf:type schema:CreativeWork
199 https://app.dimensions.ai/details/publication/pub.1079256316 schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1082752385 schema:CreativeWork
201 https://doi.org/10.1016/j.bcp.2010.04.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042899186
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.ijpharm.2013.01.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007082291
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/j.jchromb.2008.09.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011041981
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/s0140-6736(11)60070-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025413289
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/s0140-6736(15)01283-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014338125
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1021/bi901810u schema:sameAs https://app.dimensions.ai/details/publication/pub.1055210409
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1158/1078-0432.ccr-09-0360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024546443
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1158/1078-0432.ccr-14-3252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015500441
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/1535-7163.mct-04-0345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043330423
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1158/1535-7163.mct-08-0095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029470846
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2013.52.4892 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006959677
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2016.70.8297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084253732
226 rdf:type schema:CreativeWork
227 https://doi.org/10.3389/fphar.2015.00286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043813505
228 rdf:type schema:CreativeWork
229 https://doi.org/10.3390/pharmaceutics9020012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084436901
230 rdf:type schema:CreativeWork
231 https://doi.org/10.4137/bcbcr.s29421 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000921905
232 rdf:type schema:CreativeWork
233 https://www.grid.ac/institutes/grid.1006.7 schema:alternateName Newcastle University
234 schema:name Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.412917.8 schema:alternateName Christie Hospital NHS Foundation Trust
237 schema:name The Christie NHS Foundation Trust, Manchester, UK
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.418767.b schema:alternateName Eisai (United States)
240 schema:name Eisai Inc., Woodcliff Lake, NJ, USA
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.422301.6 schema:alternateName Beatson West of Scotland Cancer Centre
243 schema:name Beatson West of Scotland Cancer Centre, Glasgow, UK
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.428696.7 schema:alternateName Eisai (United Kingdom)
246 schema:name Eisai Ltd., Hatfield, UK
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.5072.0 schema:alternateName Royal Marsden NHS Foundation Trust
249 schema:name The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK
250 rdf:type schema:Organization
251 https://www.grid.ac/institutes/grid.83440.3b schema:alternateName University College London
252 schema:name UCL Cancer Institute, London, UK
253 rdf:type schema:Organization
254 https://www.grid.ac/institutes/grid.8756.c schema:alternateName University of Glasgow
255 schema:name Beatson West of Scotland Cancer Centre, Glasgow, UK
256 University of Glasgow, Glasgow, UK
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...